Drug Profile
Research programme: rotavirus vaccine - Sinovac
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Sinovac Biotech
- Class Rotavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rotavirus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Rotavirus-infections in China (Parenteral)